The largest database of trusted experimental protocols

Ct26 cells

Manufactured by Merck Group
Sourced in United States

CT26 cells are a cell line derived from mouse colon carcinoma. They are commonly used in cancer research, particularly for studies related to tumor growth and immunotherapy.

Automatically generated - may contain errors

2 protocols using ct26 cells

1

CT26 Tumor Xenograft in BALB/c Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
CT26 cells were obtained from Cell Resource Center, Chineses Academy of Medical Sciences, Beijing, China. Cells were cultured in RPMI 1640 medium (Sigma-Aldrich) supplemented with 10 % fetal bovine serum (FBS, Hyclone, USA), 100 U/ml penicillin, 100 μg/ml streptomycin, and 1 mM L-glutamine. Cultures were maintained at 37 °C with humidity and 5 % CO2.
BALB/c mice (female, 18-20 g body weight) were supplied by the Experimental Animal Center of the Fourth Military Medical University (FMMU) (Xi'an, China). In the experiment, 1 × 106 CT26 cells in 0.1 ml physiological saline were subcutaneously injected into the left oxter region of BALB/c mice. When the tumors grew to about 5 mm in diameter, mice were ready for experiments. All experiments using live animals were carried out with approval from the university's Institutional Animal Care and Use Committee.
+ Open protocol
+ Expand
2

Evaluating MK2 Inhibitor in Murine Tumor Model

Check if the same lab product or an alternative is used in the 5 most similar protocols
CT26 cell were purchased from ATCC (Manassas, VA). Cells were cultured in complete RPMI with 5% FBS, 1% penicillin/streptomycin, and 1% L-glutamine. CT26 cells were treated for 48 hours before injection with either 50uM of MK2 inhibitor PF364402 (Sigma Aldrich, St. Louis, MO) or DMSO vehicle control. Cells were injected at 105 in 50μl of PBS into the flank of 6–8 week old Balb/c mice. Some mice injected with cells exposed to MK2 inhibitors were treated with recombinant IL-1β, IL-6, and TNFα to replenish cytokine production in amounts of, 25 ng of IL-1β (Biolegend, San Diego, CA), 25 ng of TNFα (Biolegend), and 1 μg of IL-6 (Shenandoah, Warwick, PA). Treatments were administered 3 times/week from day 2 until day 13.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!